Inhibition of colorectal cancer progression through conformation-specific targeting of ADAM10 metalloprotease

Key Points

• Inhibition of colorectal cancer (CRC) growth occurs through targeting the active conformation of ADAM10, indicating a multi-pathway intervention.
• Results show this method influences oncogenic pathways associated with CRC, highlighting its therapeutic potential for treatment.
• Selective targeting strategy involves conformation-specific inhibition of ADAM10 metalloprotease to combat CRC progression more effectively.
• Therapeutic strategy's success in pre-clinical settings may enable better clinical outcomes against colorectal cancer in future evaluations.